XALKORI (crizotinib), tyrosine kinase inhibitor
Reason for request
High clinical benefit for the treatment of ALK + non-small cell lung cancer and minor clinical added value compared to platinum salt-based chemotherapy
- XALKORI has been granted a marketing authorisation for the first-line treatment of adults with advanced ALK-positive non-small cell lung cancer (NSCLC).
A study has demonstrated a gain in progression-free survival but with no impact on overall survival with XALKORI compared to platinum salt-based chemotherapy.
It is difficult to transfer the findings of the study conducted to real-life conditions of use due to different treatment schedules between the two groups.
This is a first-line treatment for advanced ALK+ NSCLC.
Clinical Added Value
Compte tenu de :
la Commission considère que XALKORI apporte une ASMR mineure (ASMR IV) dans le traitement de première ligne du CPNPC ALK+ au stade avancé.